Allopregnanolone restores the tyrosine hydroxylase-positive neurons and motor performance in a 6-OHDA-injected mouse model

Zhi-Chi Chen1,2 | Tong-Tong Wang1,2 | Wei Bian1,2 | Xin Ye1,2 | Meng-Yi Li1,2 | Juan-Juan Du2,3 | Peng Zhou1,2 | Huai-Rui Cui1 | Yu-Qiang Ding2 | Yan-hua Ren2,3 | Shuang-Shuang Qi4 | Yuan-Yuan Yuan5 | Min Liao2,3 | Chen-You Sun1,2

1Department of Anatomy, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China
2Institute of Neuroscience, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China
3Department of Histology and Embryology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China
4Department of Pharmacy, Second Affiliated Hospital, Wenzhou Medical University, Wenzhou, China
5School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China

Correspondence
Min Liao, Department of Histology and Embryology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
Email: 3590083385@qq.com
Chen-You Sun, Department of Anatomy, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
Email: sunchenyou1972@aliyun.com

Funding information
National Natural Science Foundation of China (81671401, 81701812), Wenzhou Public Welfare Science and Technology Project of China (Y20190059, Y20140725) and Research Foundation of Zhejiang Chinese Medical University (2016ZR03).

Abstract
Aims: It has been reported that allopregnanolone (APα) promotes the neurogenesis of the neural progenitor cells (NPCs) in the subventricular zone (SVZ) and prevents the decrease of dopaminergic neurons in 6-hydroxydopamine (6-OHDA)-treated mice by binding to γ-aminobutyric acid A receptor (GABAAR) and then opening voltage-gated L-type Ca2+ channel, but the underlying mechanisms remain elusive. The aim of this study was to explore the possible involvement of GABAAR and calcium/calmodulin-dependent protein kinase II delta 3 (CaMKIIδ3) in this process.

Methods: 6-OHDA-treated mice and primary cultured midbrain cells were administrated with APα and GABAAR antagonist bicuculline (Bic), and the proliferation and differentiation of NPCs, the tyrosine hydroxylase (TH)-positive neurons and their fibers, the expression levels of CaMKIIδ3 and brain-derived neurotrophic factor (BDNF), and motor functions were measured using ELISA, immunohistochemical staining, real-time RT-PCR, Western blot, and behavioral test.

Results: Allopregnanolone significantly promoted the phosphorylation of cytoplasmic CaMKIIδ3 and its nuclear translocation by binding to GABAAR, which, in turn, increased the expression levels of BDNF. This may account for the findings that the exogenous APα enhanced the proliferation and differentiation of NPCs, and ameliorated the nigrostriatal system and behavioral performance in 6-OHDA-treated mice.

Conclusions: Allopregnanolone may directly activate GABAAR, which, in turn, enhance the proliferation and differentiation of NPCs via upregulating the expression levels of CaMKIIδ3, and finally contribute to the restoration of dopaminergic neurons in 6-OHDA-treated mice.

KEYWORDS
6-hydroxydopamine, allopregnanolone, brain-derived neurotrophic factor, calcium/calmodulin-dependent protein kinase II delta 3, neural progenitor cell, γ-aminobutyric acid A receptor

Chen, Wang and Bian are contributed equally to this work.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. CNS Neuroscience & Therapeutics Published by John Wiley & Sons Ltd.
INTRODUCTION

Parkinson’s disease (PD) is characterized by the reduction of dopaminergic neurons in the substantia nigra (SN) and the subsequent dopamine depletion in the striatum. The resting tremor, movement slowness, and postural instability have become the most common clinical symptoms of PD.2,3 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydrodipyridine (MPTP) are commonly used to develop PD animal models.5,5 Some studies reported that the generation of stem cells in the subventricular zone (SVZ) lining the lateral ventricles (LVs) was inhibited in the rats or mice treated with 6-OHDA or MPTP.6,7 Another study suggested that the neurodegeneration might result from the disturbance between the neurogenesis and neuronal cell loss.8 Our previous study found that 6-OHDA-treated mice had an incomplete recovery of dopaminergic neurons in SN, suggesting that a potential therapeutic approach to promote the neurogenesis should be developed in PD treatment.9,10

Allopregnanolone (APα), which is synthesized in the embryonic and adult central nervous system (CNS), as well as in the neural progenitor cells (NPCs), shows a neurodegenerative disease-associated decline.11-12 In Alzheimer’s disease (AD) mice, some reports have indicated that APα promotes the proliferation of NPCs in the LV-SVZ, and prevents the reduction of tyrosine hydroxylase (TH)-expressed αβδ neurons in the substantia nigra (SN).21 It is likely that APα-induced proliferation and differentiation of NPCs might depend on CaMKIIαδ and BDNF, in which APα might regulate the activity of GABAAR.

In this study, 6-OHDA-treated mice and primary cultured midbrain cells were administrated with APα and/or bicuculline (Bic, a specific blocker of GABAAR) to evaluate the effects of APα and its possible molecular mechanism.

MATERIALS AND METHODS

Animals

All experiments should comply with National Institute of Health Guide for Care and Use of Laboratory Animals (NIH Publications No. 8023, revised 1978) and Animal Committee of Wenzhou Medical University. In order to identify SVZ-derived NPCs and explore their proliferation, Nestin-CreERTM::ROSA26-LacZ mice was used.9 Tamoxifen (TAM, Sigma; T5648) that was predissolved in the corn oil (15 mg/mL; vehicle solution) can activate Cre to excise the transcriptional stop cassette flanked by LoxP sites in ROSA-LacZ reporter mice and induce the expression of LacZ gene in NPCs. β-galactosidase (β-gal) that was encoded by LacZ gene could catalyze the hydrolysis of lactose and the hydrolysate showed as blue color by X-gal staining. Thus, X-gal-stained cells were regarded as Nestin-positive NPCs. Nestin-CreERTM::ROSA-LacZ mice were intraperitoneally (i.p.) injected with TAM (200 ~ 250 mg/kg/d) or the same amount of vehicle solution for five consecutive days.

A total of 3-month-old adult male Nestin-CreERTM::ROSA26-LacZ mice (n = 48) and wild-type C57BL/6 (n = 48) were maintained at a 12-hour light/dark cycle, temperature/humidity-controlled animal facility with free access to food and water. These mice were randomly assigned to normal saline + DMSO, normal saline + APα, normal saline + Bic, 6-OHDA + DMSO, 6-OHDA + APα, and 6-OHDA + APα+Bic groups. In order to develop PD mouse model, 6-OHDA (Sigma; H4381) that was predissolved in 0.02% L-ascorbate normal saline (10.26 µg/µL) was used to obtain the degeneration of dopaminergic neurons. The right side of striatum was stereotactically given 6-OHDA by a double point administration in each point having 0.487 µL according to anterior-posterior (-2.0 and -2.3 mm), mediolateral (1.0 and 0.3 mm), and dorsal-ventral (-3.5 mm) with respect to bregma using a 5-µl Hamilton syringe. In the previous studies, we found that a single 20 mg/kg of APα injection could significantly alleviate the deficiency of TH-positive neurons in AD-transgenic mouse model8,10; thus in this study, 20 mg/kg of APα (Tocris Bioscience; 3653) was subcutaneously given once on day 7 after 6-OHDA injection. In order to explore the alteration that APα exerted the neurogenic effects when the function of GABAAR was blocked by Bic, 4 mg/kg of Bic (Tocris Bioscience; 48954) was given (i.p.) to obtain an IC50 of 2 ~ 3 µmol/L at 0.5 hour prior to APα injection.22,23 In order to analyze the cell proliferation, 100 mg/kg of bromodeoxyuridine (BrdU, Sigma; B5002) was (i.p.) injected once daily for four consecutive days at 1 hour prior to 6-OHDA or APα or Bic or vehicle solution administrations. Mice were sacrificed at 2, 4, and 6 weeks following 6-OHDA for 6-OHDA + DMSO or 7, 21, and 35 days following APα or Bic administrations for 6-OHDA + APα and 6-OHDA + APα+Bic groups.

2.2 Primary culture of midbrain cells

The fetuses of pregnant SD rats were obtained on embryonic day 12. The ventral part of midbrain was dissociated into cells and maintained in 500 µL of serum-free Neurobasal medium/B27 supplement (Gibco Invitrogen; 21103049/17504044) at 37°C and 5% CO2 atmosphere. On the first day in vitro (DIV 1), these midbrain-derived cells were incubated with the mouse anti-Nestin antibody (1:400; Cell Signaling Technology; 33475S) to identify the neurospheres. Thereafter, these...
cells were divided into the control, normal saline + DMSO, normal saline + APα, normal saline + Bic, and 6-OHDA-treated groups in combination with either DMSO or 5, 50, 500 nmol/L, and 1 μmol/L concentrations of APα. The cells treated without any chemicals and reagents were used as the control group. Once the most optimal APα concentration was determined, these cells were further divided into 6-OHDA-treated group administrated with APα and/or Bic on DIV 3. In 6-OHDA + APα+Bic group, the cells were pretreated with 30 μmol/L Bic at 30 minutes prior to APα administration and then cultured for 24 hours before 0.1 mmol/L 6-OHDA was given for 24 hours. In addition, each group of cells was exposed to 10 μmol/L BrdU at 1 hour prior to 6-OHDA or APα or Bic or vehicle solution treatment.

2.3 | Behavioral test

One day prior to sacrifice, the behavioral tests were performed in sequences with a 30-minute interval.

2.3.1 | Apomorphine-induced turning behavior

Mice were injected (i.p.) with apomorphine (Sigma; 41372-20-7) at a dose of 0.125 g/L and then placed into a measuring cup to record the circles that the mice rotated toward a non-6-OHDA-injected side within 20 minutes. The apomorphine-induced turnings were expressed as circles/min.

2.3.2 | Open-field test

Each mouse was placed at the center of a 25-square floor (16 × 16 cm/square) in a box and then practiced a 5-minute session (pretest) for habituation to the new environment. On day 1 following the pretest session, the mice were allowed to explore for 5 minutes, and the total walking distance (mm) and an average walking velocity (mm/s) were recorded within 5 minutes.

2.3.3 | Rotarod test

Mice were successively placed onto a still and moving rod for 2 – 3 minutes. The speed of rod was progressively increased to 60 rpm until the mice fell off the rotating rod. The time latency (sec) and the velocity (r/min) of rotating rod were recorded before or when the mice fell off the rotating rod.

2.4 | Quantification of APα and dopamine

In order to determine the effect of exogenous APα on the endogenous APα and dopamine in 6-OHDA-injected mice, APα or dopamine concentration in the cerebral cortex or striatum was measured by comparing the optical densities (OD) of samples to the standard curve according to the manufacturer’s instruction of ELISA kit (Lab-bio Biomart). Briefly, fifty microliters of blank control, APα, or dopamine standard and tissue samples was placed into a 96-well plate that was precoated with the monoclonal anti-APα or dopamine antibody. Afterward, fifty microliters of biotin-conjugated polyclonal antibody was added and incubated for 45 minutes at 37°C. Finally, one hundred microliters of avidin-conjugated horseradish peroxidase (HRP) was added, followed by an incubation with 90 μL chromogen solution for 15 minutes at 37°C. Having added 50 μL stopping solution, the color change was assayed at 450-nm wave length using a microplate absorbance reader (Elx800, BioTek).

2.5 | X-gal and immunofluorescent staining

The staining of X-gal and immunofluorescence was performed, as reported previously with slight modifications.8-10 Briefly, six sets of sequential coronary sections (40-μm thickness) were collected. The brain sections were subjected to X-gal staining solution (Sigma; BG-3) overnight and then counterstained with 0.1% neutral red (Sigma; N4638) for 1 hour at 37°C. To analyze the proliferation and differentiation of cultured midbrain NPCs, each group of cells was incubated overnight with the rabbit anti-doublecortin (DCX; 1:400; Cell Signaling Technology; 148025) on DIV 5, or rabbit anti-β-β-tubulin III (1:400; Cell Signaling Technology; 151155) on DIV 7, or guinea pig anti-neuronal nuclear antigen (NeuN; 1:3000; Merck Millipore; ABN90) on DIV 15, or rabbit anti-TH antibodies (1:400; Merck Millipore; AB152) on DIV16 alone or in combination with the mouse anti-BrdU antibody (1:400; Novus; NB500-169). The cells were then incubated with DyLight594 goat anti-mouse or DyLight488 goat anti-rabbit secondary antibody (1:400; Jackson ImmunoResearch) for 1.5 hours at 37°C. Finally, the cells were cover-slipped with DAPI-containing mounting medium (Sigma). Negative control was carried out by replacing with normal serum or vehicle solution.

2.6 | Immunostaining for TH-positive fibers

The brain sections were incubated with the rabbit anti-TH antibody (1:400; Merck Millipore; AB152) overnight at 4°C and then incubated with the goat anti-rabbit secondary antibody (1:400; Jackson ImmunoResearch) for 2.5 hours. Finally, TH immunoreactivity was visualized by an incubation of brain sections with 0.05% diaminobenzidine (DAB; Sigma) and 0.01% H2O2 for 5 minutes.

2.7 | Real-time RT-PCR

The total RNA was prepared using TRizol Reagent (Thermo Fisher Scientific), and the relative expressions of CaMKIIα, BDNF, and CDC2 mRNAs were quantified using 2-ΔΔCT method by qPCR.
Master Mix reagent (Thermo Fisher Scientific). The mRNA expression of each sample was expressed as the percentage of normal saline + DMSO group.

2.8 Western blot

The cytoplasmic and nuclear fractions were extracted according to the manufacturer’s instruction (Beyotime). Briefly, the midbrain (~10 mg) was homogenized by sonication with 50 µL lysis buffer containing phenylmethanesulfonyl fluoride (PMSF) and phosphatase inhibitors. The lysate of brain tissue was centrifuged at 9676.8 g for 5 minutes at 4°C. The supernatant was transferred to a prechilled 1.5 mL tube (cytoplasmic protein fraction). Fifty microliters of nuclear extraction buffer was added to the tube loading the precipitation, vibrated vigorously for 30 seconds, and then incubated on ice for 2 minutes. The tube was centrifuged at 11 708.9 g for 10 minutes at 4°C, and the supernatant was transferred to a prechilled 1.5 mL tube (nuclear protein fraction).

Forty micrograms of protein that was isolated from the midbrain was run onto 10% polyacrylamide gel for 1.5 hours at 80 V and then electro-transferred onto a polyvinylidene fluoride (PVDF) membrane for 2 hours. The nonspecific binding sites were blocked with 5% nonfat milk for 2 hours. The membrane was incubated overnight at 4°C with the following primary antibodies: rabbit anti-CaMKII δ or p-CaMKII δ at 4°C with the following primary antibodies: rabbit anti-CaMKII (1:1000; Abcam; ab791) antibody. The membrane was then incubated with the corresponding HRP-conjugated goat anti-rabbit/mouse antibody (1:5000; ZSGBBIO) for 2 hours at room temperature. The immunoreactivity of protein band was detected with an enhanced chemiluminescent (ECL) kit (Beyotime). The protein level was normalized with respect to enhanced chemiluminescent (ECL) kit (Beyotime). The immunoreactivity of protein band was detected with an enhanced chemiluminescent (ECL) kit (Beyotime). The immunoreactivity of protein band was detected with an enhanced chemiluminescent (ECL) kit (Beyotime). The immunoreactivity of protein band was detected with an enhanced chemiluminescent (ECL) kit (Beyotime).

2.9 Co-immunoprecipitation assay

According to the manufacturer’s instruction (Absin), 10% cytoplasmic or nuclear fraction from the midbrain was taken out as an input (positive control). Meanwhile, the remaining extract was coated with 1~5 µg of rabbit anti-CaMKII δ or p-CaMKII δ antibody (Abcam) or IgG (negative control) overnight at 4°C. The extract was then incubated with Protein A and G Sepharose beads (1:1) for 3 hours at 4°C. The magnetic beads were washed thoroughly for 3 times. The input and immunoprecipitation were undertaken by Western blot analysis for CDK1 or BDNF.

2.10 Image acquisition, cell counting, and statistical analysis

According to the atlas of mouse brain,24 every sixth brain section was collected. An unbiased stereological estimation was made in TH-positive neurons and X-gal-positive cells from 16 randomly selected frames. In the primarily cultured midbrain cells, the immunopositive cells were counted by randomly selecting five visual fields. In order to measure the OD of striatal TH-positive fibers, five brain sections were obtained. The immunoreactivity and immunopositive cells were captured under an upright microscope (Olympus) and calculated using ImageJ software (NIH). To identify the colocalization of double-positive cells, the confocal laser scanning microscope (NIKON A1R) was used to make a 3D (x-y, x-z, and y-z) reconstruction. Statistical analysis was displayed with Prism 7.04 software (GraphPad Software Inc). All data were presented as mean ± SEM and analyzed by repeated measures of one-way ANOVA or two-way ANOVA followed by Bonferroni post hoc test. The differences were statistically significant when the probability (P) value was less than or equal to .05, .01, .001, and .0001.

3 RESULTS

3.1 APα ameliorated the deficits of balance and coordination in 6-OHDA-administrated mice

The open-field and rotarod tests, as well as the rotational behavior, which mirrored the abilities of balance and coordination, were conducted. 6-OHDA-administrated mice displayed a stronger turning behavior toward a noninjected side in response to the apomorphine, as well as a much worse behavioral performance in the open-field and rotarod tests, as compared with the pretest, and normal saline + DMSO- or normal saline + APα or normal saline + Bic-treated mice. There was not significantly different among the pretest, normal saline + DMSO-, normal saline + APα or normal saline + Bic-treated mice. Moreover, the turning behavior was significantly alleviated at 6 weeks, as compared with that at 2 week following 6-OHDA injection. APα ameliorated the rotational behavior, and reversed the behavioral deficits of 6-OHDA-lesioned mice in the open-field and rotarod tests. Notably, the rotational circles were much less on day 21 and 35 following APα administration. Importantly, APα-induced behavioral amelioration was blocked by Bic administration (Figure 1A ~ E).

3.2 APα reversed the striatal dopamine level in 6-OHDA-injected mice

Since SN dopaminergic neurons projected their axon terminals into the striatum, we examined the striatal dopamine level. There was a significant reduction in the striatal dopamine level of 6-OHDA + DMSO group, as compared with normal saline + DMSO, normal saline + APα, and normal saline + Bic-treated groups. There was not significantly different among the normal saline + DMSO-, normal saline + APα-, and normal saline + Bic-treated mice.
Moreover, the striatal dopamine level was much higher at 6 weeks than that at 2 weeks following 6-OHDA injection (P = .0041). APα significantly increased the striatal dopamine level of 6-OHDA + DMSO group, and in particular, there was a striatal dopamine turnover on day 21 and 35 following APα administration (P = .0015). It should be noted that these effects were blocked by Bic treatment (Figure 1F).

3.3 Bic blocked the elevation of APα level in the cerebral cortex of 6-OHDA-injected mice

In the CNS, APα was mainly synthesized in the cerebral cortex of adult mammal animals, so we examined APα concentration in the cerebral cortex. There was a significant reduction in APα content of 6-OHDA + DMSO group at 2 and 4 weeks following 6-OHDA injection,
as compared with normal saline + DMSO−, normal saline + APα−, and normal saline + Bic-treated groups. When the exogenous APα was injected to 6-OHDA-treated mice, an increase in APα content occurred on day 7 and 21 following APα injection (P = .0063), and this change was blocked again by Bic treatment. However, there did not exist a significant difference among groups at 6 weeks following 6-OHDA injection (Figure 1G).

3.4 Administered APα protected the nigrostriatal system against 6-OHDA lesion

6-OHDA was stereotaxically injected into the striatum to induce the lesion of nigrostriatal system. The dopaminergic neurons and their fibers were immunostained with anti-TH (rate-limiting enzyme for dopamine biosynthesis) antibody. TH-positive neurons were observed in the SNpc of normal saline + DMSO (A), normal saline + APα (B), normal saline + Bic (C), 6-OHDA + DMSO (D), 6-OHDA + APα (E), and 6-OHDA + APα+Bic (F). (G)–(L), DAB-stained TH-positive fibers were observed in the striatum of normal saline + DMSO (G), normal saline + APα (H), normal saline + Bic (I), 6-OHDA + DMSO (J), 6-OHDA + APα (K), and 6-OHDA + APα+Bic (L). SNpc, pars compacta of substantia nigra; VTA, ventral tegmental area; CPu, striatum. Scale bar = 200 μm for images (A)–(L). (M) and (N), Absolute number of TH-positive neurons in the SNpc (M) and the OD of TH-positive fibers in the striatum (N) at 2, 4, and 6 wk following 6-OHDA injection. Values are mean ± SEM; n = 3 at various time points for each group. **P < .0001, comparison between 6-OHDA + DMSO and normal saline + DMSO or normal saline + APα or normal saline + Bic groups; ^P < .01, ^^^^P < .0001, and ^^^^^P < .00001, comparison between 6-OHDA + APα and 6-OHDA + DMSO groups; &P < .05, &&&P < .0001, comparison between 6-OHDA + APα+Bic and 6-OHDA + APα groups; $P < .05$, comparison between at 2 and 6 wk following 6-OHDA injection in the striatal TH-positive fibers; ^^P < .01 and ^^^^^P < .0001, comparison between on day 7 and 21 or 35 following APα injection in SNpc TH-positive neurons using Two-way ANOVA followed by Bonferroni post hoc test. NS, no significance.
neurons in the SN exhibited green immunofluorescence in the perikarya and proximal dendrites (Figure 2A ~ F), and TH-positive fibers in the striatum displayed brown reaction products (Figure 2G ~ L).

The mice treated with 6-OHDA had an approximate 71.9%, 58.9%, and 58.05% loss in SNpc TH-positive neurons, as well as 70.50%, 65.50%, and 57.53% reduction in striatal TH-positive fibers at 2, 4, and 6 weeks following 6-OHDA injection, as compared with normal saline + DMSO. There was not significantly different among the normal saline + DMSO-, normal saline + APα-, and normal saline + Bic-treated mice. Moreover, a slight recovery in TH-positive axon terminals began at 6 weeks following 6-OHDA injection (P = .0208). APα significantly augmented the number of SNpc TH-positive neurons and OD of their striatal fibers of 6-OHDA + DMSO group, and in particular, there was a significant increase in TH-positive neurons on day 21 and 35 following APα administration (P = .0163, P = .0021). In addition, Bic significantly reduced SNpc TH-positive neurons and striatal TH immunoreactivity after APα treatment (Figure 2M ~ N).
CHEN ET AL.

3.5 APα administration further increased the number of Nestin-positive NPCs in 6-OHDA-injected mice

Our findings showed that X-gal-labeled Nestin-positive NPCs with blue products were prevalent in the SVZ of LV (LV-SVZ), third ventricle (3V-SVZ), and cerebral aqueduct (Aq-SVZ) (Figure 3A–C). Relative to normal saline + DMSO group, the ratio of NPCs at 2, 4, and 6 weeks following 6-OHDA injection was 391.67%, 553.85%, and 156.25% in LV-SVZ, 298.46%, 800.00%, and 106.25% in 3V-SVZ, as well as 122.32%, 687.50%, and 286.67% in Aq-SVZ, respectively. A peak increase in Nestin-positive NPCs of these SVZ occurred at 4 weeks following 6-OHDA injection. There was not significantly different among the normal saline + DMSO-, normal saline + APα-, and normal saline + Bic-treated mice. APα further increased the number of Nestin-positive NPCs in these SVZ, particularly at 4 weeks following 6-OHDA injection. In addition, Bic partly abolished APα-induced increase in NPCs of SVZ (Figure 3D–F).

FIGURE 4 (A)–(E), Neural stem cells (A), immature NPCs (B), developing neurons (C), mature neurons (D) and dopaminergic neurons (E) were detected using anti-Nestin, DCX, β-tubulin III, NeuN, and TH antibodies on DIV 1, 5, 7, 15, and 16, respectively. A representative image of DCX, β-tubulin III, NeuN and TH-positive cells (green color), and BrdU-positive cells (red color) was shown to verify their colocalization in three planes (x, y, and z) by confocal laser scanning microscope. Scale bar = 200, 50, and 100 μm for images (A), (B) and (C)–(E). (F)–(I), The number of DCX, BrdU or DCX/BrdU (F), β-tubulin III, BrdU or β-tubulin III/BrdU (G), NeuN, BrdU or NeuN/BrdU (H), and TH, BrdU or TH/BrdU-positive cells (I) was calculated per field among different groups. Values are mean ± SEM; n = 3 at various time points for each group. **P < .01, ***P < .001, and ****P < .0001, comparison between 6-OHDA + DMSO and control group or normal saline + DMSO or normal saline + 500 nmol/L APα or normal saline + Bic groups; #P < .05, ##P < .01, ###P < .001, and ####P < .0001, comparison between 6-OHDA + 500 nmol/L APα and 6-OHDA + DMSO groups; *P < .05, **P < .01, ***P < .001, and ****P < .0001, comparison between 6-OHDA + 500 nmol/L APα + Bic and 6-OHDA + 500 nmol/L APα groups by repeated measures of one-way ANOVA followed by Bonferroni post hoc test. NS, no significance.

(A) (B) (C) (D) (E) (F) (G) (H) (I)
3.6 | APα administration promoted the proliferation and differentiation of 6-OHDA-treated midbrain-derived NPCs

To explore the effects of APα on the NPCs of midbrain, the embryonic midbrain-derived cells were cultured. A majority of cultured midbrain cells could form neurospheres on DIV 1 (Figure 4A). After these cells were exposed to BrdU for 48 hours, BrdU-positive cells exhibited a medium-sized round or oval nucleus, which resembled a chromatin-like structure (Figure 4B – E). BrdU-labeled newborn midbrain-derived cells were dramatically decreased in 6-OHDA-treated group, as compared with the control group, normal saline + DMSO, normal saline + APα, and normal saline + Bic groups. A series of concentrations of APα (5 nmol/L ~ 1 μmol/L) significantly increased the number of newborn midbrain-derived cells. Moreover, 500 nmol/L APα was selected as the most optimal APα concentration in promoting the proliferation of these newborn midbrain-derived cells (data not shown).

To further investigate the differentiation of midbrain-derived BrdU-positive newborn cells, we performed a double immunofluorescence staining. DCX-positive immature NPCs exhibited a cluster morphology, β-tubulin III-positive cells showed a prominent nucleus and neurite extension, NeuN was localized within the nuclear fraction, and TH was mainly present in the cytoplasm (Figure 4B – E). After an incubation with BrdU for 48 hours, BrdU-positive cells were coexpressed with DCX (43.8831 ± 4.5595%) on DIV 5, β-tubulin III (49.1615 ± 2.4661%) on DIV 7, NeuN (1.8316 ± 0.8350%) on DIV 15, and TH (2.5895 ± 0.0570%) on DIV 16 in the control group. 6-OHDA significantly decreased the number of DCX and TH/BrDU-positive cells. The most optimal concentration (500 nmol/L) of APα significantly increased these positive cells of 6-OHDA + DMSO group. In addition, Bic significantly decreased these double-positive cells of 6-OHDA + 500 nmol/L APα group (Figure 4F – I).

3.7 | APα treatment increased the phosphorylation of cytoplasmic CaMKIIδ3 and its nuclear translocation in 6-OHDA-lesioned mice

Since APα could open VGLCC in immature neurons, we speculated that it might regulate the expression levels of Caβ3/CaM-dependent protein kinases. Our morphological results demonstrated that CaMKIIδ3 was located in the multiple brain areas including the cerebral cortex, hippocampal dentate gyrus, SN, ventral tegmental area, LV, 3V-, and Aq-SVZ, and their surrounding regions (data not shown).

The relative expression levels of CaMKIIδ3 mRNA in the midbrain were much lower in 6-OHDA + DMSO group than those in the normal saline + APα or normal saline + Bic-treated mice at 2 and 6 weeks following 6-OHDA treatment. There was not significantly different among the normal saline + DMSO-, normal saline + APα, and normal saline + Bic-treated mice at 2 and 4 weeks following 6-OHDA administration. As compared with 6-OHDA + DMSO group, the relative expression levels of CaMKIIδ3 mRNA were significantly elevated after APα administration, and they were the highest on day 35 following APα administration. These effects were blocked by Bic treatment (Figure 5B).

The effect of APα on total CaMKIIδ3 or p-CaMKIIδ3 expression levels was further validated by Western blot assay (Figure 5A). The total CaMKIIδ3 or p-CaMKIIδ3 expression levels in the midbrain were significantly decreased after 6-OHDA treatment, as compared with normal saline + DMSO or normal saline + APα or normal saline + Bic groups. There was not significantly different among the normal saline + DMSO-, normal saline + APα, and normal saline + Bic-treated mice. Nevertheless, p-CaMKIIδ3 expression levels were much higher in the cytoplasmic fraction of midbrain at 6 weeks than those at 2 and 4 weeks following 6-OHDA injection. APα significantly increased the total CaMKIIδ3 or p-CaMKIIδ3 expression levels on day 7 and 14 or 35 following APα administration, in particular, p-CaMKIIδ3 expression levels were much higher in the cytoplasmic fraction of midbrain on day 21 and 35 than those on day 7 following APα administration. In addition, Bic significantly reduced the total CaMKIIδ3 or p-CaMKIIδ3 expression levels on day 7 or 21 or 35 following APα administration (Figure 5C – F). Interestingly, our results showed that APα-induced a ratio of p-CaMKIIδ3/totalCaMKIIδ3 expression levels in the nuclear fraction was approximately 2.14-fold higher than that in the cytoplasmic fraction of midbrain.

3.8 | APα treatment increased the expression levels of BDNF, CDK1, CDC2 or p-CDC2 in the mRNAs or proteins of 6-OHDA-lesioned mice

The neurogenic action of APα predicted that it could regulate the neurotrophic factors and cell cycle proteins, so we examined the expression levels of BDNF and nuclear cyclin-dependent kinase-1 (CDK1) or cell division cycle protein 2 homolog (CDC2). Like CaMKIIδ3 mRNA expression levels, the relative expression levels of BDNF and CDC2 mRNAs in the midbrain were much lower in 6-OHDA + DMSO group than those in normal saline + DMSO or normal saline + APα and normal saline + Bic groups at 2 and 4 weeks following 6-OHDA treatment. There was not significantly different among the normal saline + DMSO-, normal saline + APα, and normal saline + Bic-treated mice. APα administration resulted in a significant upregulation, which was reversed by Bic administration (Figure 6A-B). Western blot assay indicated that the protein expression levels of BDNF, CDK1, and p-CDC2 had an entire consistence with their mRNAs expression levels at 2 or 4 or 6 weeks following 6-OHDA treatment (Figure 6C,D – F).

3.9 | Co-immunoprecipitation assay determined the interactions of CaMKIIδ3 or p-CaMKIIδ3 and BDNF or CDK1

To determine the interaction of total CaMKIIδ3 or p-CaMKIIδ3 with CDK1 or BDNF, co-immunoprecipitation was performed. Our results demonstrated that a small fraction of CDK1 and BDNF were also present in the cytoplasmic fraction, although they were mainly located
in the nuclear fraction of midbrain. Co-immunoprecipitation assay revealed that total CaMKIIδ3 and p-CaMKIIδ3 predominantly bound to BDNF or CDK1 in the nuclear fraction of midbrain (Figure 6G-H).

4 | DISCUSSION

Our current results indicated that 6-OHDA-induced reduction in TH-positive fibers and the dopamine level terminally led to a massive loss of TH-positive neurons, which was consistent with the previous reports.26,27 Nevertheless, we also noticed there was a partial recovery at 6 weeks following 6-OHDA injection involving the striatal dopamine level or TH-positive axon terminals, which seemed to be related to a substantial increase in X-gal-labeled Nestin-positive NPCs at 4 weeks following 6-OHDA injection by a postlesion compensatory mechanism. Although the neuronal death or degeneration could induce a modest increase in NPCs division or their neurogenesis,28,29 their proliferation and differentiation could
not keep up with the degenerative processes in an unfavorable microenvironment.20

In the aged and AD brains, a previous research has shown that there was a significant decrease in APα content, which was associated with a decrease in SNpc TH-positive neurons.10,31 Our current research further proved that APα treatment partly recovered the APα and dopamine levels in PD mice, which terminately protected the nigrostriatal TH-positive neurons against 6-OHDA lesion. Some studies indicated that APα regulated the neurogenesis of SVZ-NPCs by binding to GABAAR and then opening L-type Ca2+ channel.14,32,33 Once APα site within GABAAR was blocked by Bic, APα-induced amelioration was abolished not only in SN-striatal TH-positive neurons but also in the proliferation and differentiation of newborn midbrain-derived NPCs; however, Bic alone could not significantly decrease these indicators, suggesting that APα required GABAAR to promote the neurogenesis of NPCs.
GABAAR was a ligand-gated chloride channel including a variety of subunits, and our results indicated that APα administration could significantly alleviate the expression levels of GABAAR α4 subunit in the membrane protein fraction of midbrain at 2 and 4 weeks following 6-OHDA injection (P = .0244, P = .0022), which was significantly reversed on day 21 after pretreatment with Bic (P = .0447) (data not shown), but it did not suggest whether GABAARs was in a validated functional state. However, some studies reported that APα could induce a significant alteration in GABAAR expression levels by activating many GABAAR subtypes including GABAARα1 and GABAARβ2 in promoting the proliferation of NPCs, neuronal migration, synaptogenesis, and hippocampal neurogenesis. 14,15,18

In the adult hippocampal neurogenesis, APα binding to GABAAR-induced rise in the cytoplasmic Ca2+ concentration was often followed by the activation of gene transcription and intracellular cascades. 14,15,18 Some studies reported that the cytoplasmic Ca2+ /CaM activated and promoted the phosphorylation of CaMKII and its nuclear translocation, leading to the expressions of transcription factors and BDNF, which, in turn, promoted the neurite extension in 6-OHDA-lesioned dopaminergic neurons. 24,25 In CaMKII isoforms, our results indicated that CaMKIIα was mainly located in the regions where NPCs were abundant except for SN and the striatum. 21 As compared with the cytoplasmic fraction, APα could induce a higher ratio of p-CaMKIIα/total CaMKIIα in the nuclear fraction, indicating APα treatment enhanced the phosphorylation of cytoplasmic CaMKIIα and its nuclear translocation in 6-OHDA-lesioned mice, which was in accordance with a previous report. 26 However, a conflicting study indicated that p-CaMKIIα was dephosphorylated and then easily translocated into the nuclear fraction after the dopamine receptor was activated. 27 This discrepancy might result from the idea that the assembly of CaMKII isoforms likely affected its activation and nuclear translocation. 28

Mohapel et al 28 found that BDNF increased the number of newly formed cells in the striatum and SN of adult rats with a unilateral SN 6-OHDA lesion. In the course of APα-induced SVZ neurogenesis, BDNF phosphorylation was also elevated. 29 In addition, APα could significantly upregulate the expression of proliferating cell nuclear antigen, cyclins, and CDKs. 30,31 Our studies demonstrated that APα increased CaMKIIα3, BDNF, and CDC2 expression levels of 6-OHDA-lesioned mice via GABAAR by transcriptional and translational mechanisms. In addition, we also found that p-CaMKIIα3 or total CaMKIIα3 had an interaction with CDK1 or BDNF, indicating that APα-induced increase in the phosphorylation of cytoplasmic CaMKIIα3 and its nuclear translocation further promoted their interactions with the cell cycle protein and BDNF, which, in turn, further increased these proteins expression levels.

Some studies and our previous results indicated that a small amount of SNpc newly generated TH-positive neurons might be involved in the regeneration process of 6-OHDA-lesioned dopaminergic neurons. 9,41-44 Our current results from the primarily cultured midbrain cells indicated that 6-OHDA treatment could inhibit the acquisition of neuronal identities and reduce the newly generated midbrain-derived NPCs differentiation toward mature neurons, which was not in line with Nestin-positive NPCs in vivo study because a local unfavorable microenvironment could upregulate the number of Nestin-positive NPCs with the absence of dopaminergic inputs. 7 In addition, APα induced an extremely rare increase in the newborn dopaminergic neurons, which further supported that the newly formed NPCs and their differentiation contributed a small fraction to APα-promoted regeneration process following 6-OHDA lesion, indicating that the newborn mature neurons were formed after a strong selection of NPCs. 44,45

Some documents reported that APα increased the function of surviving dopaminergic neurons in a neighboring area to compensate the dysfunction from the lesioned neurons, which, in turn, enhanced the behavioral performance. 14-16,46 Other studies indicated that APα reinstated TH-positive neurons and their fibers, as well as the motor symptoms in MPTP-lesioned mice. 8,17,19 Although there was a partial recovery in the turning behavior at 6 weeks following 6-OHDA injection except for p-CaMKIIα3 expression, our results indicated that APα treatment could further improve the motor performance in PD mice, accompanying with a significant increase in TH-positive neurons and their fibers or dopamine levels, as well as the number of NPCs. However, the detail mechanisms underlying APα-ameliorated behavioral performance in 6-OHDA-lesioned mice need to be further elucidated.

In conclusion, a vital contribution of the presented work is that APα/GABAAR/CaMKIIα3 might be an alternative molecular and cellular mechanism that underlies APα-treated PD.

ACKNOWLEDGMENTS

We gratefully acknowledge Mr Tserai Hilton Munyaradzi for his excellent work in language revision.

CONFLICT OF INTERESTS

The authors declare no conflict of interest.

ORCID

Chen-You Sun https://orcid.org/0000-0002-4563-1987

REFERENCES

1. Morrison BE. Discovery of nigral dopaminergic neurogenesis in adult mice. Neuroal Regen Res. 2016;11:878-881.
2. Broen M, Duits A, Visser-Vandewalle V, et al. Impulse control and related disorders in Parkinson's disease patients treated with bilateral subthalamic nucleus stimulation: a review. Parkinsonism Relat Disord. 2011;17:413-417.
3. Wu K, Politis M, Piccini P. Parkinson disease and impulse control disorders: a review of clinical features, pathophysiology and management. Postgrad Med J. 2009;85:590-596.
4. Zuch CL, Nordstroem VK, Briedrick LA, et al. Time course of degenerative alterations in nigral dopaminergic neurons following a 6-hydroxydopamine lesion. J Comp Neurol. 2000;427:440-454.
5. Deumens R, Blokland A, Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol. 2002;175:303-317.
6. Baker SA, Baker KA, Hagg T. Dopaminergic nigrostriatal projections regulate neural precursor proliferation in the adult mouse subventricular zone. Eur J Neurosci. 2004;20:575-579.
7. Winner B, Geyer M, Couillard-Despres S, et al. Striatal deafferentation increases dopaminergic neurogenesis in the adult olfactory bulb. Exp Neurol. 2006;197:113-121.

8. Sun C, Ou X, Farley JM, et al. Allopregnanolone increases the number of dopaminergic neurons in substantia nigra of a triple transgenic mouse model of Alzheimer’s disease. Curr Alzheimer Res. 2012;9:473-480.

9. Xie MQ, Chen ZC, Zhang P, et al. Newborn dopaminergic neurons are associated with the migration and differentiation of SVZ-derived neural progenitors in a 6-hydroxydopamin-injected mouse model. Neuroscience. 2017;352:64-78.

10. Zhang P, Xie MQ, Ding YQ, et al. Allopregnanolone enhances the neurogenesis of midbrain dopaminergic neurons in APPswe/PSEN1 mice. Neuroscience. 2015;290:214-226.

11. Brinton RD, Wang JM. Therapeutic potential of neurogenesis for prevention and recovery from Alzheimer’s disease: allopregnanolone as a proof of concept neurogenic agent. Curr Alzheimer Res. 2016;3:185-190.

12. Gago N, El-Etr M, Sananes N, et al. 3alpha,5alpha-Tetrahydroprogesterone (allopregnanolone) and gamma-aminobutyric acid: autocrine/paracrine interactions in the control of neuronal PSA-NCAM+ progenitor proliferation. J Neurosci. 2004;78:770-783.

13. Marx CE, Trost WT, Shampine LJ, et al. The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer’s disease. Biol Psychiatry. 2006;60:1287-1294.

14. Wang JM, Johnston PB, Ball BG, et al. The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression. J Neurosci. 2005;25:4706-4718.

15. Wang JM, Singh C, Liu L, et al. Allopregnanolone reverses neurogenic and genetic deficits in mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A. 2010;107:649-6503.

16. Singh C, Liu L, Wang JM, et al. Allopregnanolone restores hippocampal-dependent learning and memory and neural progenitor survival in aging 3xTgAD and nonTg mice. Neurobiol Aging. 2012;33:1493-1506.

17. Adenosyn SO, Hou X, Jiao Y, et al. Allopregnanolone reinstates tyrosine hydroxylase immunoreactive neurons and motor performance in an MPTP-lesioned mouse model of Parkinson’s disease. PLoS One. 2012;7:e50040.

18. Jagasia R, Steib K, Englberger E, et al. GABA-cAMP response element-binding proteinsignaling regulates maturation and survival of newly generated neurons in the adult hippocampus. J Neurosci. 2009;29:7966-7977.

19. Keller EA, Zamparini A, Borodinsky LN, et al. Role of allopregnanolone on cerebellar granule cells neurogenesis. Brain Res Dev Brain Res. 2004;153:13-17.

20. Fukunaga K, Miyamoto E. A working model of CaM kinase II activity in hippocampal long-term potentiation and memory. Neurosci Res. 2000;38:3-17.

21. Takeuchi Y, Fukunaga K, Miyamoto E. Activation of nuclear Ca(2+)/calmodulin dependent protein kinase II and brain-derived neurotrophic factor gene expression by stimulation of dopamine D2 receptor in transfected NG108-15 cells. J Neurochem. 2002;82:316-328.

22. Yunès R, Casas S, Gaglio E, et al. Progesterone exerts a neuro-modulatory effect on turning behavior of hemiparkinsonian male rats: expression of 3α-hydroxysteroid oxidoreductase and allopregnanolone as suggestive of GABAA receptors involvement. Parkinsonism Dis. 2015;2015:431690.

23. Rodriguez-Landa JF, Contreras CM, Garcia-Rios RL. Allopregnanolone microinjected into the lateral septum or dorsal hippocampus reduces immobility in the forced swim test: participation of the GABAA receptor. Behav Pharmacol. 2009;20:614-622.

24. Golmohammadi MG, Blackmore DG, Large B, et al. Comparative analysis of the frequency and distribution of stem and progenitor cells in the adult mouse brain. Stem Cells. 2008;26:979-987.

25. Parish CL, Belajeva A, Arenas E, et al. Midbrain dopaminergic neurogenesis and behavioural recovery in a salamander lesion-induced regeneration model. Development. 2007;134:2881-2887.

26. Grospe GM, Baker PM, Ragozzino ME. Cognitive flexibility deficits following 6-OHDA lesions of the rat dorsomedial striatum. Neuroscience. 2018;374:80-90.

27. Wasik A, Romanska I, Zelek-Molik A, et al. Multiple administration of endogenous amines TIQ and 1MeTIQ protects against a 6-OHDA-induced essential fall of dopamine release in the rat striatum. Vivo Microdialysis Study. Neurotox Res. 2018;33:523-531.

28. Emsley JG, Mitchell BD, Kempermann G, et al. Adult neurogenesis and repair of the adult CNS with neural progenitors, precursors, and stem cells. Prog Neurobiol. 2005;75:321-341.

29. Park J, Enikolopov G. Transient elevation of adult hippocampal neurogenesis after dopamine depletion. Exp Neurol. 2010;222:267-276.

30. Lie DC, Song H, Colamarino SA, et al. Neurogenesis in the adult brain: new strategies for central nervous system diseases. Annu Rev Pharmacol Toxicol. 2004;44:399-421.

31. Charalampopoulos I, Remboutsika E, Margioris AN, et al. Neurosteroids as modulators of neurogenesis and neuronal survival. Trends Endocrinol Metab. 2008;19:300-307.

32. Guennoun R, Meffre D, Labombarda F, et al. The membrane-associated progesterone-binding protein 25-Dx: expression, cellular localization and up-regulation after brain and spinal cord injuries. Brain Res Rev. 2008;57:493-505.

33. Schumacher M, Guennoun R, Ghoumari A, et al. Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system. Endocrinol Rev. 2007;28:387-439.

34. Ma H, Groth RD, Cohen SM, et al. gammaCaMKII shuttles Ca(2+)/CaM to the nucleus to trigger CREB phosphorylation and gene expression. Cell. 2014;159:281-294.

35. Shioda N, Sawai M, Ishizuka Y, et al. Nuclear translocation of calcium/ calmodulin-dependent protein kinase IIdelta3 promoted by protein phosphatase-1 enhances brain-derived neurotrophic factor expression in dopaminergic neurons. J Biol Chem. 2015;290:21663-21675.

36. Heist EK, Srinivasan M, Schulman H. Phosphorylation at the nuclear localization signal of Ca2+/calmodulin-dependent protein kinase II blocks its nuclear targeting. J Biol Chem. 1998;273:19763-19771.

37. Aponso PM, Faul RL, Connor B. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson’s disease. Neuroscience. 2008;151:1142-1153.

38. Mohapel P, Frielingdorf H, Haggblad J, et al. Platelet-derived growth factor (PDGFB) and brain-derived neurotrophic factor (BDNF) induce striatal neurogenesis in adult rats with 6-hydroxydopamine lesions. Neuroscience. 2005;132:767-776.

39. Schulman BA, Carrano AC, Jeffrey PD, et al. Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex. Nature. 2000;408:381-386.

40. Tyers M, Jorgensen P. Proteolysis and the cell cycle: with this RING I do thee destroy. Curr Opin Genet Dev. 2000;10:54-64.

41. Höglnder GU, Rizk P, Muriel MP, et al. Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci. 2004;7:726-735.

42. Yamada M, Iwatsubo T, Mizuno Y, et al. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson’s disease. J Neurochem. 2004;91:451-461.

43. Shan X, Chi L, Bishop M, et al. Enhanced de novo neurogenesis and dopaminergic neurogenesis in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson’s disease-like mice. Stem Cells. 2006;24:1280-1287.
44. Luzzati F, De Marchis S, Fasolo A, et al. Adult neurogenesis and local neuronal progenitors in the striatum. *Neurodegener Dis*. 2007;4:322-327.

45. Zhao M, Momma S, Delfani K, et al. Evidence for neurogenesis in the adult mammalian substantianigra. *Proc Natl Acad Sci U S A*. 2003;100:7925-7930.

46. Gage FH. Neurogenesis in the adult brain. *J Neurosci*. 2002;22:612-613.